Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06776588

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy

Led by Beidahuang Industry Group General Hospital · Updated on 2025-11-24

200

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.

CONDITIONS

Official Title

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 75 years or younger
  • Ground-glass nodule patients with lesion size 3 cm or less in maximum axial diameter
  • Refusal of radical surgery or inability to tolerate surgical treatment
  • Normal coagulation function with platelet count at least 60 × 10⁹/L
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less
Not Eligible

You will not qualify if you...

  • Lesion size greater than 3 cm in maximum axial diameter
  • Platelet count less than 50 × 10⁹/L
  • Severe bleeding tendency or coagulation dysfunction not correctable shortly
  • Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis, or pulmonary hypertension
  • Anticoagulant or antiplatelet therapy stopped less than 5 days before ablation
  • Severe heart, liver, kidney, or brain dysfunction
  • Severe anemia, dehydration, or cachexia not correctable shortly
  • Estimated survival less than 6 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beidahuang Industry Group General Hospital

Harbin, Heilongjiang, China, 150088

Actively Recruiting

Loading map...

Research Team

M

Mingyang Liu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here